Delving into the Latest Updates on ICA-105665 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Mechanism

Kv7.2 agonists(Voltage-gated potassium channel subunit Kv7.2 agonists), Kv7.3 stimulants(Potassium voltage-gated channel subfamily KQT member 3 stimulants)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication-

Inactive Indication

EpilepsyEpilepsy, ReflexHyperalgesia+ [1]

Originator Organization

Icagen, Inc.

Active Organization-

Inactive Organization

Icagen, Inc.

Pfizer Inc.

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Subjects with epilepsy with a documented photoparoxysmal response to intermittent photic stimulation (IPS) will participate. Four subjects will be enrolled at each dose level and will receive a single dose of placebo and a single dose of ICA-105665 during the study, each followed by intermittent photic stimulation. The effects of ICA-105665 on the photoparoxysmal electroencephalography (EEG) response of each group will be reviewed before the dose is selected for each subsequent group of subjects.

Start Date01 Sep 2009

Sponsor / Collaborator

Pfizer Inc.

NCT00962663 / CompletedPhase 1

A Randomized, Placebo-Controlled, 3-way Crossover Study to Investigate the Pharmacodynamic Effects of ICA-105665 Using the Intradermal Capsaicin and UV-B Models in Healthy Male Subjects

The purpose of this study is; to determine the pharmacodynamic (PD) effects of ICA-105665 using the intradermal (ID) capsaicin model in healthy male subjects, and to investigate the effect of ICA-105665 on inflammatory hyperalgesia using the ultraviolet B (UV-B) model in healthy male subjects.

Start Date01 Aug 2009

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with ICA-105665

Login to view more data

100 Translational Medicine associated with ICA-105665

Login to view more data

100 Patents (Medical) associated with ICA-105665

Login to view more data

7

Literatures (Medical) associated with ICA-105665

01 Feb 2016·Pharmacological ResearchQ2 · MEDICINE

Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical development

Q2 · MEDICINE

Review

Author: Schmidt, Dieter ; Zaccara, Gaetano

Currently information is available for 20 potential anti-seizure drugs in clinical development. They include candidates with mechanisms of action similar to those of marketed AEDs (allopregnanolone, brivaracetam, ganaxolone, ICA-105665, NS1209, selurampanel); those with new mechanisms of action (beprodon, VX-765); compounds repurposed for the treatment of epilepsy (biperiden, bumetanide, fenfluramine, melatonin, nalutozan, pitolisant, quinidine, valnoctamide, verapamil); and finally candidates with currently unknown mechanisms of action (JNJ-26489112, UCB0942, YKP3089 (Cenobamate). Clinical development of anti-seizure drugs is still active but unexciting. Potential anti-seizure drugs continue to be largely identified by their activity against seizures provoked by electrical or chemical procedures in animals with normal brains. As in the past, this may lead to new drugs whose efficacy is not better than that of those already on the market.

01 Aug 2013·EpilepsiaQ1 · MEDICINE

Kv7 potassium channel activation with ICA‐105665 reduces photoparoxysmal EEG responses in patients with epilepsy

Q1 · MEDICINE

Article

Author: Rosenfeld, William E. ; Diventura, Bree ; Rigdon, Greg C. ; Biton, Victor ; Moore, Elizabeth L. ; French, Jacqueline A. ; Abou‐Khalil, Bassel ; Hetherington, Seth V. ; Kasteleijn‐Nolst Trenité, Dorotheé G. A.

SummaryPurposeTo assess the effects of ICA‐105665, an agonist of neuronal Kv7 potassium channels, on epileptiform EEG discharges, evoked by intermittent photic stimulation (IPS), the so‐called photoparoxysmal responses (PPRs) in patients with epilepsy.MethodsMale and female patients aged 18–60 years with reproducible PPRs were eligible for enrollment. The study was conducted as a single‐blind, single‐dose, multiple‐cohort study. Four patients were enrolled in each of the first three cohorts. Six patients were enrolled in the fourth cohort and one patient was enrolled in the fifth cohort. PPR responses to 14 IPS frequencies (steps) were used to determine the standard photosensitivity range (SPR) following placebo on day 1 and ICA‐105665 on day 2. The SPR was quantified for three eye conditions (eyes closing, eyes closed, and eyes open), and the most sensitive condition was used for assessment of efficacy. A partial response was defined as a reduction in the SPR of at least three units at three separate time points following ICA‐105665 compared to the same time points following placebo with no time points with more than three units of increase. Complete suppression was defined by no PPRs in any eye condition at one or more time points.Key FindingsSix individual patients participated in the first three cohorts (100, 200, and 400 mg). Six patients participated in the fourth cohort (500 mg), and one patient participated in the fifth cohort (600 mg). Decreases in SPR occurred in one patient at 100 mg, two patients receiving 400 mg ICA‐105665 (complete abolishment of SPR occurred in one patient at 400 mg), and in four of six patients receiving 500 mg. The most common adverse events (AEs) were those related to the nervous system, and dizziness appeared to be the first emerging AE. The single patient in the 600 mg cohort developed a brief generalized seizure within 1 h of dosing, leading to the discontinuation of additional patients at this dose, per the predefined protocol stopping rules.SignificanceICA‐105665 reduced the SPR in patients at single doses of 100 (one of four), 400 (two of four), and 500 mg (four of six). This is the first assessment of the effects of activation of Kv7 potassium channels in the photosensitivity proof of concept model. The reduction of SPR in this patient population provides evidence of central nervous system (CNS) penetration by ICA‐105665, and preliminary evidence that engagement with neuronal Kv7 potassium channels has antiseizure effects.

01 Jan 2013·Epilepsy ResearchQ3 · MEDICINE

Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI)

Q3 · MEDICINE

Review

Author: Meir Bialer ; Torbjörn Tomson ; H. Steve White ; René H. Levy ; Svein I. Johannessen ; Emilio Perucca

The Eleventh Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT XI, took place in Eilat, Israel from the 6th to 10th of May 2012. About 100 basic scientists, clinical pharmacologists and neurologists from 20 countries attended the conference, whose main themes included "Indications overlapping with epilepsy" and "Securing the successful development of an investigational antiepileptic drug in the current environment". Consistent with previous formats of this conference, a large part of the program was devoted to a review of AEDs in development, as well as updates on AEDs introduced since 1994. Like the EILAT X report, the current manuscript focuses only on the preclinical and clinical pharmacology of AEDs that are currently in development. These include brivaracetam, 2-deoxy-glucose, ganaxolone, ICA-105665, imepitoin, NAX 801-2, perampanel and other AMPA receptor antagonists, tonabersat, valnoctamide and its homologue sec-propylbutylacetamide (SPD), VX-765 and YK3089. Since the previous Eilat conference, retigabine (ezogabine) has been marketed and four newer AEDs in development (NAX 810-2, SPD, tonabersat and VX-765) are included in this manuscript.

100 Deals associated with ICA-105665

Login to view more data